Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Role of PTEN Gene Expression and Length of Survival of Breast Cancer Patients in the North East of Iran

  • Golmohammadi, Rahim (Anatomy Department, Sabzevar University of Medical Sciences) ;
  • Rakhshani, Mohammad Hassan (Biostatistics Department, School of Health, Sabzevar University of Medical Sciences) ;
  • Moslem, Ali Reza (Anesthesiology Department, Sabzevar University of Medical Sciences) ;
  • Pejhan, Akbar (Physiology Department, School of Medicine, Sabzevar University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

PTEN protein is an important tumour suppressor factor detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN gene expression focusing on length of survival in breast cancer patients. This descriptive-analytical study was conducted on 100 breast cancer cases referred to Sabzevar hospitals in the north east of Iran between 2010 and 2011, followed up to 2015. The PTEN gene expression of tumour tissue samples was determined using specific monoclonal antibodies. The data were analyzed using Chi-square test and Fisher's exact test. Patient length of survival was analyzed after 4 years of follow-up using the Cox regression model. The PTEN gene was expressed in 70 of 100 samples, while being found at a high level in all noncancerous samples. There was an inverse significant relationship between expression of PTEN and tumour stage and grade (p<0.001). In addition, expression of PTEN in invasive ductal tumours was less than in non-invasive tumours. There was also an inverse significant relationship between the likelihood of death and PTEN gene expression (p<0.01). These findings indicate that lack of PTEN gene expression can be sign for a worse prognosis and poor survival in breast cancer.

Keywords

References

  1. Baig RM, Mahjabeen I, Sabir M, et al (2011). Genetic changes in the PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev, 12, 2773-8.
  2. Bogdanova N, Helbig S, Dork T (2013). Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract, 11, 12. https://doi.org/10.1186/1897-4287-11-12
  3. Boosani CS, Agrawal DK (2013). PTEN modulators: a patent review. Expert Opin Ther Pat, 23, 569-80. https://doi.org/10.1517/13543776.2013.768985
  4. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16. https://doi.org/10.1634/theoncologist.9-6-606
  5. Dean SJ, Perks CM, Holly JM, et al (2014). Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol, 141, 323-33. https://doi.org/10.1309/AJCPR11DEAYPTUSL
  6. De- Assis LV, Isoldi MC (2013). The function, mechanisms, and role of the genes PTEN and P53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol, 35, 889-901.
  7. Dunning AM, Healey CS, Pharoah PD, et al (1999). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 843-54.
  8. Golmohammadi R, Pejhan A (2012).The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc, 62, 871-5.
  9. Golmohammadi R, Namazi MJ, Nikbakht M, et al (2013). Characterization and prognostic value of mutations in exons 5 and 6 of the p53 gene in patients with colorectal Cancers in Central Iran. Gut Liver, 7, 295-302. https://doi.org/10.5009/gnl.2013.7.3.295
  10. Gori S, Sidoni A, Colozza M, et al (2009). EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with rastuzumab. Ann Oncol, 20, 648-54. https://doi.org/10.1093/annonc/mdn681
  11. Jones N, Bonnet F, Sfar S, et al (2013). Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer, 133, 323-34. https://doi.org/10.1002/ijc.28021
  12. Kafshdooz L, Kafshdooz T, Tabrizi AD, et al (2015). Role of exon 7 PTEN Gene in Endometrial Carcinoma. Asian Pac J Cancer Prev, 16, 4521-4. https://doi.org/10.7314/APJCP.2015.16.11.4521
  13. Kitagishi Y, Matsuda S (2013). Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med, 31, 511-5. https://doi.org/10.3892/ijmm.2013.1235
  14. Koo DH, Lee HJ, Ahn JH, et al (2015). Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol, 36, 5865-71. https://doi.org/10.1007/s13277-015-3258-9
  15. Kumar V, Cotran R, Robbins S. et al (2007). Robbins Basic Pathology 8th Edition, Saunders Elsevier, Philadelphia pp 739-50.
  16. Lam WW, Fielding R, Ho EY (2005). Predicting psychological morbidity in Chinese women after surgery for breast carcinoma. Cancer, 103, 637-46. https://doi.org/10.1002/cncr.20810
  17. Mandal RK, Akhter N, Irshad M, et al (2015). Association of the PTEN IVS4 (rs3830675) gene polymorphism with reduced risk of cancer: evidence from a meta-analysis. Asian Pac J Cancer Prev, 16, 897-902. https://doi.org/10.7314/APJCP.2015.16.3.897
  18. Mayo LD, Dixon JE, Durden DL, et al (2002). PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J Biol Chem, 277, 5484-9. https://doi.org/10.1074/jbc.M108302200
  19. Neto JC, Ikoma MM, Carvalho KC, et al (2012). MGMT and PTEN as potential prognostic markers in breast cancer. Exp Mol Pathol, 92, 20-6. https://doi.org/10.1016/j.yexmp.2011.09.019
  20. Okutur K, Bassulu N, Dalar L, et al (2015). Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer. Asian Pac J Cancer Prev, 16, 2645-51. https://doi.org/10.7314/APJCP.2015.16.7.2645
  21. Sakr RA, Barbashina V, Morrogh M, et al (2010). Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol, 18, 371-4. https://doi.org/10.1097/PAI.0b013e3181d50bd5
  22. Sharif MA, Mamoon N, Arif A, et al (2009). Histological and immuno-histochemical study of male breast carcinoma in Northern Pakistan. J Pak Med Assoc, 59, 67-71.
  23. Song MS, Salmena L, Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283-96. https://doi.org/10.1038/nrm3330
  24. Troyer DA, Jamaspishvili T, Wei W, et al (2015). A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 11, 1206-15.
  25. Tsutsui S, Inoue H, Yasuda K, et al (2005). Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology, 68, 398-404. https://doi.org/10.1159/000086981
  26. Van-den Broek AJ, Broeks A, Horlings HM, et al (2011). Association of the germ line TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. Breast Cancer Res Treat, 130, 599-608. https://doi.org/10.1007/s10549-011-1615-y
  27. Wan W, Zou H, Sun R, et al (2007). Cell Signal. Investigate the role of PTEN in chemotaxis of human breast cancer cells. Cell Signal, 19, 2227-36. https://doi.org/10.1016/j.cellsig.2007.06.007
  28. Wang S, Gao J, Lei Q, et al (2003). Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-21. https://doi.org/10.1016/S1535-6108(03)00215-0
  29. Wikman H, Lamszus K, Detels N, et al (2012). Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res, 14, 49.
  30. Yang J, Ren Y, Wang L, et al (2010). PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol, 136, 1303-11. https://doi.org/10.1007/s00432-010-0781-3
  31. Yu L, Yang Y, Hou J, et al (2015). Micro RNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep, 34, 1845-52. https://doi.org/10.3892/or.2015.4173
  32. Zhang AX, Lu FQ, Yang YP, et al (2015). Micro RNA-217 over expression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. Cell Biol Int, 11, 1299-306.
  33. Zhang HY, Liang F, Jia ZL, et al (2013). PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett, 6, 161-8. https://doi.org/10.3892/ol.2013.1331
  34. Zhou M, Gu L, Findley HW, et al (2003). PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res, 63, 6357-62.

Cited by

  1. Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317695529
  2. The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients vol.96, pp.36, 2017, https://doi.org/10.1097/MD.0000000000008000
  3. MicroRNA-126 regulates the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway in SLK cells in vitro and the expression of its pathway members in Kaposiʼs sarcoma tissue vol.97, pp.35, 2018, https://doi.org/10.1097/MD.0000000000011855